Zobrazeno 1 - 10
of 1 760
pro vyhledávání: ''
Autor:
Paul Mitchell, G Rivalland, Hui Yu, Fred R. Hirsch, R. Mosher, L Churilov, K Asadi, Christopher J. Rivard, S Heynemann
Publikováno v:
Clinical Lung Cancer. 23:e90-e98
Background NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumours including breast, thyroid, ovarian and non-sm
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:565-575
Purpose: NRAS plays a pivotal role in progression of various kinds of somatic malignancies; however, the correlation between NRAS and lung adenocarcinoma is less known. We aim to analyze the prognostic value of NRAS expression in lung adenocarcinoma,
Publikováno v:
Modern Pathology. 34:1738-1749
Invasive stratified mucin-producing carcinoma (ISMC) is a recently described entity of human papillomavirus (HPV)-associated endocervical adenocarcinoma with phenotypic plasticity and aggressive clinical behavior. To identify the cell of origin of IS
Autor:
Mai Iwaya, Tomoyuki Nakajima, Takayuki Watanabe, Yusuke Miyagawa, Yasuhiro Kinugawa, Takeshi Uehara, Takashi Muraki, Yasuhiro Kuraishi, Takeji Umemura
Publikováno v:
Diagnostic Pathology, Vol 16, Iss 1, Pp 1-8 (2021)
Diagnostic Pathology
Diagnostic Pathology
Background Pancreaticobiliary maljunction (PBM) is a condition characterized by chronic inflammation due to refluxed pancreatic juice into the biliary tract that is associated with an elevated risk of biliary tract cancer. DNA double-strand breaks (D
Autor:
Yoshihiro Komohara, Toshiyuki Shima, Masayuki Shimoda, Remi Mito, Yusuke Shinchi, Koei Ikeda, Makoto Suzuki, Takuro Sakagami, Eri Matsubara, Yae Kanai, Yukio Fujiwara
Publikováno v:
Pathology International. 71:666-673
CD163 is one of the scavenger receptors expressed on macrophages. However, several immunohistochemical studies have demonstrated that CD163 is also detected on cancer cells, and is associated with a poor prognosis. In the present study, we detected C
Autor:
Yoshihiko Murata, Tomoki Nakagawa, Yunjung Kim, Junko Kano, Masayuki Noguchi, Zeinab Kosibaty, Noriaki Sakamoto
Publikováno v:
Pathology International
The expression of Ras-specific guanine nucleotide-releasing factor 2 (RasGRF2) in lung adenocarcinomas was examined using immunohistochemistry in relation to clinicopathological characteristics and prognosis. In comparison to low expression, high exp
Autor:
Bin Zhao, Yang Zhai, Lina Li, Jingjin Li, Linhan Chang, Zijun Liao, Yuzhen Wang, Qian Chen, Xu Li
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Lung adenocarcinoma (LUAD) is the most common pathology subtype of lung cancer. In recent years, immunotherapy, targeted therapy and chemotherapeutics conferred a certain curative effects. However, the effect and prognosis of LUAD patients
Autor:
Junyi Ye, Shanai Song, Haiwei Du, Zhou Zhang, Haiyan Li, Ning Liu, Zimin Liu, Xiaoxiao Li, Lu Zhang, Mingpeng Shi
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The identification of HER2 overexpression in a subset of gastric adenocarcinoma (GA) patients represents a significant step forward in unveiling the molecular complexity of this disease. The predictive and prognostic value of HER2 amplificati
Autor:
Mariana Petaccia de Macedo, Carlos Barrios, Eduardo Caetano Albino da Silva, Gustavo Werutsky, Clovis Klock, G. Borges, Christina Shiang, Fernando Silva de Moura, Vladmir Cláudio Cordeiro de Lima, Luiz H. Araujo, Eldsamira Mascarenhas, Paulo Ricardo Santos Nunes Filho, Pedro De Marchi, Helano C. Freitas, Facundo Zaffaroni, Patricia Pacheco Viola, A. Gelatti, Lisandro Ferreira Lopes, Mauro Zukin, Ana Maria Franco Gaiger, Clarissa Mathias
Publikováno v:
Clinical Lung Cancer. 21:e511-e515
Introduction We analyzed the prevalence of non–small-cell lung cancer (NSCLC) with a programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥ 50% and compared the results with the existing data from clinical trials and databases f
Publikováno v:
Cancer Cytopathology. 129:148-155
BACKGROUND Immune checkpoint inhibitor therapy has revolutionized lung adenocarcinoma therapy. Treatment with antibodies against the immune checkpoint molecules programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) can induce a durable resp